サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1536202

肺水腫治療の世界市場

Pulmonary Edema Therapeutics

出版日
ページ情報
英文 285 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
肺水腫治療の世界市場
出版日: 2024年08月16日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 285 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

肺水腫治療の世界市場は2030年までに24億米ドルに達する見込み

2023年に21億米ドルと推定される肺水腫治療の世界市場は、分析期間2023-2030年にかけてCAGR 1.7%で成長し、2030年には24億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである心原性肺水腫治療は、CAGR 1.9％を記録し、分析期間終了までに15億米ドルに達すると予測されます。非心原性肺水腫治療セグメントの成長率は、分析期間でCAGR 1.4％と推定されます。

米国市場は5億8,410万米ドル、中国はCAGR 3.7％で成長予測

米国の肺水腫治療市場は、2023年に5億8,410万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに4億6,300万米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは3.7%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.3%と1.2%と予測されています。欧州では、ドイツがCAGR約0.7%で成長すると予測されています。

世界の肺水腫治療市場- 主な促進要因と動向まとめ

肺水腫は、肺の気嚢内に液体が蓄積し、ガス交換障害や呼吸困難を引き起こすことを特徴とする重篤な病状です。この状態は、うっ血性心不全、急性呼吸窮迫症候群（ARDS）、高所、特定の毒素や薬剤への曝露など、さまざまな原因によって生じる可能性があります。肺水腫の治療の第一目標は、過剰な体液を除去し、酸素化を改善し、根本的な原因に対処することです。治療的アプローチには通常、患者固有の病態と重症度に応じて、薬理学的介入と非薬理学的介入を組み合わせる。

肺水腫の薬理学的治療には、主にフロセミドなどの利尿薬が含まれ、腎臓からの排泄を促進することで体液貯留を抑制します。ニトログリセリンのような血管拡張薬も血管内の圧力を低下させるために使用され、心臓の仕事量を減らし、肺の体液蓄積を緩和するのに役立ちます。肺水腫の原因が心不全である場合は、心機能を改善するためにACE阻害薬やβ遮断薬などの薬剤が処方されます。非薬物療法としては、血液中の酸素濃度を改善するための酸素療法や、重症例では呼吸を補助するための機械的人工呼吸が行われます。さらに、塩分摂取量の減少や水分バランスの管理などの生活習慣の改善は、肺水腫を起こしやすい慢性疾患を有する患者の長期管理に不可欠な要素です。

肺水腫治療市場の成長は、いくつかの要因によってもたらされます。第一に、肺水腫の主な原因である心血管疾患の有病率の増加が、効果的な治療に対する需要を大幅に押し上げています。第二に、医学研究の進歩により、より優れた有効性と安全性プロファイルを提供する、新しく改良された薬理学的治療法の開発が進んでいます。心臓関連の疾患や呼吸器系の問題を抱えやすい世界人口の高齢化は、市場の成長をさらに促進しています。さらに、新興市場におけるヘルスケアインフラの拡大と高度医療へのアクセスが、肺水腫治療の利用可能性を高めています。製薬企業と研究機関の戦略的提携により、革新的な治療法の発見と商業化が加速しています。最後に、医療従事者や患者の肺水腫に対する意識の高まりと早期診断が、タイムリーで効果的な治療介入への需要を促進し、市場の成長軌道を確固たるものにしています。

調査対象企業の例（注目の86社）

  • Bayer AG
  • Citius Pharmaceuticals, Inc.
  • Edesa Biotech
  • Exponential Biotherapies
  • Genentech, Inc.
  • Lupin Ltd.
  • Pantherna Therapeutics GmbH
  • Pfizer Inc.
  • Qx Therapeutics, Inc.
  • Sun Pharmaceutical Industries Ltd.;

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP26614

Global Pulmonary Edema Therapeutics Market to Reach US$2.4 Billion by 2030

The global market for Pulmonary Edema Therapeutics estimated at US$2.1 Billion in the year 2023, is expected to reach US$2.4 Billion by 2030, growing at a CAGR of 1.7% over the analysis period 2023-2030. Cardiogenic Pulmonary Edema Therapeutics, one of the segments analyzed in the report, is expected to record a 1.9% CAGR and reach US$1.5 Billion by the end of the analysis period. Growth in the Non-Cardiogenic Pulmonary Edema Therapeutics segment is estimated at 1.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$584.1 Million While China is Forecast to Grow at 3.7% CAGR

The Pulmonary Edema Therapeutics market in the U.S. is estimated at US$584.1 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$463.0 Million by the year 2030 trailing a CAGR of 3.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.3% and 1.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 0.7% CAGR.

Global Pulmonary Edema Therapeutics Market - Key Drivers and Trends Summarized

Pulmonary edema is a serious medical condition characterized by the accumulation of fluid in the lungs' air sacs, leading to impaired gas exchange and difficulty breathing. This condition can result from various causes, including congestive heart failure, acute respiratory distress syndrome (ARDS), high altitude, and exposure to certain toxins or medications. The primary goal of pulmonary edema treatment is to remove the excess fluid, improve oxygenation, and address the underlying cause. Therapeutic approaches typically involve a combination of pharmacological and non-pharmacological interventions, tailored to the patient's specific condition and severity.

Pharmacological treatments for pulmonary edema primarily include diuretics, such as furosemide, which help to reduce fluid accumulation by promoting its excretion through the kidneys. Vasodilators like nitroglycerin are also used to decrease the pressure in the blood vessels, reducing the workload on the heart and helping to alleviate fluid buildup in the lungs. In cases where pulmonary edema is caused by heart failure, medications like ACE inhibitors or beta-blockers may be prescribed to improve heart function. Non-pharmacological treatments can include oxygen therapy to improve oxygen levels in the blood and mechanical ventilation in severe cases to support breathing. Additionally, lifestyle modifications, such as reducing salt intake and managing fluid balance, are essential components of long-term management for patients with chronic conditions that predispose them to pulmonary edema.

The growth in the pulmonary edema therapeutics market is driven by several factors. Firstly, the increasing prevalence of cardiovascular diseases, which are a major cause of pulmonary edema, has significantly boosted the demand for effective treatments. Secondly, advancements in medical research have led to the development of new and improved pharmacological therapies that offer better efficacy and safety profiles. The aging global population, which is more prone to heart-related conditions and respiratory issues, has further fueled market growth. Additionally, the expansion of healthcare infrastructure and access to advanced medical care in emerging markets has increased the availability of pulmonary edema treatments. Strategic collaborations between pharmaceutical companies and research institutions are accelerating the discovery and commercialization of innovative therapies. Lastly, heightened awareness and early diagnosis of pulmonary edema among healthcare professionals and patients have driven the demand for timely and effective therapeutic interventions, solidifying the market's growth trajectory.

Select Competitors (Total 86 Featured) -

  • Bayer AG
  • Citius Pharmaceuticals, Inc.
  • Edesa Biotech
  • Exponential Biotherapies
  • Genentech, Inc.
  • Lupin Ltd.
  • Pantherna Therapeutics GmbH
  • Pfizer Inc.
  • Qx Therapeutics, Inc.
  • Sun Pharmaceutical Industries Ltd.;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Pulmonary Edema Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Cardiovascular and Respiratory Diseases Drives Demand for Pulmonary Edema Therapeutics
    • Advancements in Diagnostic Technologies Enhance Early Detection and Treatment
    • Growing Awareness of Respiratory Health Boosts Market Demand for Therapeutics
    • Rising Incidence of Acute Pulmonary Edema and Influence on Market Dynamics
    • Development of Targeted Therapies and Precision Medicine Propels Market Growth
    • Advances in Biotechnology Drive Development of Novel Pulmonary Edema Treatments
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Pulmonary Edema Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Pulmonary Edema Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Pulmonary Edema Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Cardiogenic Pulmonary Edema by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Cardiogenic Pulmonary Edema by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Cardiogenic Pulmonary Edema by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Non-Cardiogenic Pulmonary Edema by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Non-Cardiogenic Pulmonary Edema by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Non-Cardiogenic Pulmonary Edema by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Pulmonary Edema Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • JAPAN
    • Pulmonary Edema Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • CHINA
    • Pulmonary Edema Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • EUROPE
    • Pulmonary Edema Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Pulmonary Edema Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Pulmonary Edema Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • FRANCE
    • Pulmonary Edema Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • GERMANY
    • Pulmonary Edema Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Pulmonary Edema Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Pulmonary Edema Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Pulmonary Edema Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Pulmonary Edema Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Pulmonary Edema Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • INDIA
    • Pulmonary Edema Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: India 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: India 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Pulmonary Edema Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Pulmonary Edema Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Pulmonary Edema Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Pulmonary Edema Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Pulmonary Edema Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Pulmonary Edema Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • AFRICA
    • Pulmonary Edema Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030

IV. COMPETITION